Transconjunctival versus Transcutaneous Injection of Botulinum Toxin into the Lacrimal Gland to Reduce Lacrimal Production: A Randomized Controlled Trial.

MLA

Lee, Andrew G., et al. “Transconjunctival versus Transcutaneous Injection of Botulinum Toxin into the Lacrimal Gland to Reduce Lacrimal Production: A Randomized Controlled Trial.” Toxins, vol. 13, no. 2, Jan. 2021. EBSCOhost, https://doi.org/10.3390/toxins13020077.

APA

Lee, A. G., Lee, S.-H., Jang, M., Lee, S. J., & Shin, H. J. (2021). Transconjunctival versus Transcutaneous Injection of Botulinum Toxin into the Lacrimal Gland to Reduce Lacrimal Production: A Randomized Controlled Trial. Toxins, 13(2). https://doi.org/10.3390/toxins13020077

Chicago

Lee, Andrew G, Shin-Hyo Lee, Minsu Jang, Sang Jae Lee, and Hyun Jin Shin. 2021. “Transconjunctival versus Transcutaneous Injection of Botulinum Toxin into the Lacrimal Gland to Reduce Lacrimal Production: A Randomized Controlled Trial.” Toxins 13 (2). doi:10.3390/toxins13020077.